These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 33624138)

  • 1. Novel homozygous variant in BMP1 associated with a rare osteogenesis imperfecta phenotype.
    Choksi IN; Cox A; Robinson C; Bale A; Carpenter TO
    Osteoporos Int; 2021 Jun; 32(6):1239-1244. PubMed ID: 33624138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic variability in patients with osteogenesis imperfecta caused by BMP1 mutations.
    Pollitt RC; Saraff V; Dalton A; Webb EA; Shaw NJ; Sobey GJ; Mughal MZ; Hobson E; Ali F; Bishop NJ; Arundel P; Högler W; Balasubramanian M
    Am J Med Genet A; 2016 Dec; 170(12):3150-3156. PubMed ID: 27576954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased fracture rate, pharmacogenetics and BMD response in 79 Swedish children with osteogenesis imperfecta types I, III and IV treated with Pamidronate.
    Lindahl K; Kindmark A; Rubin CJ; Malmgren B; Grigelioniene G; Söderhäll S; Ljunggren Ö; Åström E
    Bone; 2016 Jun; 87():11-8. PubMed ID: 26957348
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel compound heterozygous mutations in SERPINH1 cause rare autosomal recessive osteogenesis imperfecta type X.
    Song Y; Zhao D; Xu X; Lv F; Li L; Jiang Y; Wang O; Xia W; Xing X; Li M
    Osteoporos Int; 2018 Jun; 29(6):1389-1396. PubMed ID: 29520608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel mutations in BMP1 result in a patient with autosomal recessive osteogenesis imperfecta.
    Xi L; Lv S; Zhang H; Zhang ZL
    Mol Genet Genomic Med; 2021 Jun; 9(6):e1676. PubMed ID: 33818922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up in osteogenesis imperfecta type VI.
    Trejo P; Palomo T; Montpetit K; Fassier F; Sato A; Glorieux FH; Rauch F
    Osteoporos Int; 2017 Oct; 28(10):2975-2983. PubMed ID: 28689307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two novel compound heterozygous BMP1 mutations in a patient with osteogenesis imperfecta: a case report.
    Sangsin A; Kuptanon C; Srichomthong C; Pongpanich M; Suphapeetiporn K; Shotelersuk V
    BMC Med Genet; 2017 Mar; 18(1):25. PubMed ID: 28257626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
    Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
    J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective Proteolytic Processing of Fibrillar Procollagens and Prodecorin Due to Biallelic BMP1 Mutations Results in a Severe, Progressive Form of Osteogenesis Imperfecta.
    Syx D; Guillemyn B; Symoens S; Sousa AB; Medeira A; Whiteford M; Hermanns-Lê T; Coucke PJ; De Paepe A; Malfait F
    J Bone Miner Res; 2015 Aug; 30(8):1445-56. PubMed ID: 25656619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mutations in BMP1 induce a rare type of osteogenesis imperfecta.
    Xu XJ; Lv F; Song YW; Li LJ; Asan ; Wei XX; Zhao XL; Jiang Y; Wang O; Xing XP; Xia WB; Li M
    Clin Chim Acta; 2019 Feb; 489():21-28. PubMed ID: 30408480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonate therapy for osteogenesis imperfecta.
    Phillipi CA; Remmington T; Steiner RD
    Cochrane Database Syst Rev; 2008 Oct; (4):CD005088. PubMed ID: 18843680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study.
    Otaify GA; Aglan MS; Ibrahim MM; Elnashar M; El Banna RA; Temtamy SA
    Osteoporos Int; 2016 Jan; 27(1):81-92. PubMed ID: 26138583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of Pathogenic Mutations and Responses to Zoledronic Acid in a Cohort of Osteogenesis Imperfecta Children.
    Sun L; Hu J; Liu J; Zhang Q; Wang O; Jiang Y; Xia W; Xing X; Li M
    J Clin Endocrinol Metab; 2022 Aug; 107(9):2571-2579. PubMed ID: 35727737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of quality of life, functional and bone outcomes in osteogenesis imperfecta with bisphosphonate therapy initiated in childhood or adulthood.
    Feehan AG; Zacharin MR; Lim AS; Simm PJ
    Bone; 2018 Aug; 113():137-143. PubMed ID: 29787832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Skeletal outcomes of patients with osteogenesis imperfecta during drug holiday of bisphosphonates: a real-world study.
    Zhang Y; Hu J; Lin X; Sun L; Yan S; Zhang Q; Jiang Y; Wang O; Xia W; Xing X; Li M
    Front Endocrinol (Lausanne); 2022; 13():901925. PubMed ID: 36225201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD005088. PubMed ID: 27760454
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bisphosphonate therapy for osteogenesis imperfecta.
    Dwan K; Phillipi CA; Steiner RD; Basel D
    Cochrane Database Syst Rev; 2014 Jul; (7):CD005088. PubMed ID: 25054949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZOLEDRONIC ACID VERSUS ALENDRONATE IN THE TREATMENT OF CHILDREN WITH OSTEOGENESIS IMPERFECTA: A 2-YEAR CLINICAL STUDY.
    Lv F; Liu Y; Xu X; Song Y; Li L; Jiang Y; Wang O; Xia W; Xing X
    Endocr Pract; 2018 Feb; 24(2):179-188. PubMed ID: 29466057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement.
    Letocha AD; Cintas HL; Troendle JF; Reynolds JC; Cann CE; Chernoff EJ; Hill SC; Gerber LH; Marini JC
    J Bone Miner Res; 2005 Jun; 20(6):977-86. PubMed ID: 15883638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a mutation causing deficient BMP1/mTLD proteolytic activity in autosomal recessive osteogenesis imperfecta.
    Martínez-Glez V; Valencia M; Caparrós-Martín JA; Aglan M; Temtamy S; Tenorio J; Pulido V; Lindert U; Rohrbach M; Eyre D; Giunta C; Lapunzina P; Ruiz-Perez VL
    Hum Mutat; 2012 Feb; 33(2):343-50. PubMed ID: 22052668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.